arrow
D

Dorota Dybowska

Nicolaus Copernicus University
H指数:13
被引数:403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland

在战争难民涌入波兰期间,乌克兰裔患者中丙型肝炎病毒感染的治疗

2024-12-150
OAAI
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices

HCV感染的肝硬化和食管静脉曲张患者直接抗病毒治疗的真实世界经验

2024-08-201
OAAI
Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders

在丙型肝炎病毒精神障碍患者中直接抗病毒药物的真实世界有效性和安全性

2023-07-076
OAAI
Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
2023-04-0711
OAAI
Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
2022-09-018
OAAI
HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study
2022-01-134
OA
Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
2021-07-2517
OAAI
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
2021-05-1411
OAAI
Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study

肝硬化和肝功能失代偿史患者直接抗病毒药物的真实世界有效性和安全性: Epi-Ter2研究

2021-03-1818
PREAI
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

在现实世界中,格列卡普雷韦/皮布伦他韦的8周治疗方案是否足以满足所有感染丙型肝炎病毒的患者?

2020-11-2311
PREAI
Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA
2020-06-2714
PREAI
Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection
2020-02-0724
OA
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously difficult to treat patients infected with hepatitis C virus genotype 1 and 4
2020-01-169
PREAI